[1] American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl 1:S62-9.
[2] Ding N, Kwak L, Ballew SH, et al. Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2018;274:86-93.
[3] Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011;34(6):e61-99.
[4] Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800-11.
[5] Andersson C, Johnson AD, Benjamin EJ, et al. 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol. 2019;16(11):687-698.
[6] Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
[7] Sarah Rosner P, Pencina MJ, Shih-Jen H, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the framingham heart study. Circulation. 2009;120(3):212-20.
[8] Kang DO, Seo HS, Choi BG, et al. Absolute change in fasting plasma glucose over 12 months is associated with 2-year and 5-year major adverse cardiovascular events in patients with drug-eluting stent implants. Int J Cardiol. 2015;179:146-52.
[9] Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.
[10] Liu XJ, Wan ZF, Zhao N, et al. Adjustment of the GRACE score by HemoglobinA1c enables a more accurate prediction of long-term major adverse cardiac events in acute coronary syndrome without diabetes undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2015;14:110.
[11] Ashraf H, Boroumand MA, Amirzadegan A, et al. Hemoglobin A1C in non-diabetic patients: an independent predictor of coronary artery disease and its severity. Diabetes Res Clin Pract. 2013;102(3):225-32.
[12] Chen CL, Yen DH, Lin CS, et al. Glycated hemoglobin level is an independent predictor of major adverse cardiac events after non fatal acute myocardial infarction in nondiabetic patients: a retro spective observational study. Medicine (Baltimore). 2017;96(18):e6743.
[13] Açar B, Ozeke O, Karakurt M,et al. Association of Prediabetes With Higher Coronary Atherosclerotic Burden Among Patients With First Diagnosed Acute Coronary Syndrome. Angiology. 2019;70(2):174-180.
[14] Scicali R, Giral P, Gallo A, et al. HbA1c increase is associated with higher coronary and peripheral atherosclerotic burden in non diabetic patients. Atherosclerosis. 2016;255:102-8.
[15] Blake GJ, Pradhan AD, Manson JE, et al. Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med. 2004;164(7):757-61.
[16] ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
[17] Min YW, Song BG, Kim HS, et al. Associations between reflux esophagitis and the progression of coronary artery calcification: A cohort study. PLoS One. 2017;12(10):e0184996.
[18] Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827-32.
[19] Ajudani R, Rezaee-Zavareh MS, Karimi-Sari H, et al. Glycosylated haemoglobin and coronary atherosclerosis in non-diabetic patients: is it a prognostic factor? Acta Cardiol. 2017;72(5):522-528.
[20] Zhao W, Katzmarzyk PT, Horswell R, et al. HbA1c and coronary heart disease risk among diabetic patients. Diabetes Care. 2014;37(2):428-35.
[21] Rivera JJ, Choi EK, Yoon YE, et al. Association between increasing levels of hemoglobin A1c and coronary atherosclerosis in asymptomatic individuals without diabetes mellitus. Coron Artery Dis. 2010;21(3):157-63.
[22] Reaven PD, Moritz TE, Schwenke DC,et al. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009;58(11):2642-8.
[23] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
[24] Svanteson M, Holte KB, Haig Y, et al. Coronary plaque characteristics and epicardial fat tissue in long term survivors of type 1 diabetes identified by coronary computed tomography angiography. Cardiovasc Diabetol. 2019;18(1):58.
[25] Lindholt JS, Frystyk J, Hallas J, et al. Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes. Clin Epidemiol. 2020;12:447-455.
[26] Jung CH, Lee WY, Kim SY, et al. The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol. 2010;47 Suppl 1:145-52.
[27] Yang J, Zhou Y, Zhang T, et al. Fasting Blood Glucose and HbA1c Correlate With Severity of Coronary Artery Disease in Elective PCI Patients With HbA1c 5.7% to 6.4. Angiology. 2020;71(2):167-174.
[28] Rhee EJ, Cho JH, Kwon H, et al. Association Between Coronary Artery Calcification and the Hemoglobin Glycation Index: The Kangbuk Samsung Health Study. J Clin Endocrinol Metab. 2017;102(12):4634-4641.
[29] Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. Lancet Diabetes Endocrinol. 2016;4(2):115-24.